FDA Approvals and Global Health Updates: Major Pharmaceutical Developments

The latest health news covers significant updates including the FDA's approval of Citius Pharmaceuticals' and Novartis' new therapies, Merck's halt on a lung cancer drug trial, Gilead Sciences' profit triumph, concerns over Gaza's child health amidst conflict, Novavax's revenue cuts, endorsement of RSV vaccines for elderly in Germany, Biocon's profit surge post-sale, booming sales of Eli Lilly’s weight-loss drug, and Africa CDC's potential mpox emergency declaration.

The latest health news briefs capture key pharmaceutical advancements and global health concerns. The U.S. Food and Drug Administration approved innovative treatments by Citius Pharmaceuticals and Novartis targeting rare blood cancer and kidney disease patients respectively, while Merck halted a lung cancer drug trial due to adverse effects.

Gilead Sciences reported robust second-quarter profits driven by reduced costs and increased product sales, and Eli Lilly raised its sales forecast amid the booming demand for its weight-loss drug Zepbound. Conversely, Novavax announced a trimmed revenue forecast and reduced European presence, adapting strategies amidst competitive COVID-19 vaccine market dynamics.

Global health issues also prompt attention, as Gaza's children suffer from widespread skin diseases in war conditions and Africa CDC plans to declare an mpox emergency. Additionally, Germany's vaccine panel advocates RSV vaccines for the elderly, and Biocon's Q1 profit soars following the sale of its branded formulations business. These updates reflect the dynamic landscape of health interventions and challenges worldwide.

(With inputs from agencies.)